cyclo(RLsKDK) TFA

cyclo(RLsKDK) TFA

C659213-5mg

5mg

≥98%

避光,充氩,干燥,-80℃储存

超低温冰袋运输

cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC 50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer. Appearance:Solid In Vitro:cyclo(RLsKDK) (TFA) promotes ADAM8 activation and CD23 shedding with IC 50 values of 120 nM and 182 nM, respectively. cyclo(RLsKDK) (TFA) (200 nM; 0-120 h) increases activity of pro-ADAM8. cyclo(RLsKDK) (TFA) (200 nM and 500 nM; 12 h) promotes t In Vivo:cyclo(RLsKDK) (TFA) (10 µg/g; i.p.; once weekly for 4 weeks) significantly reduces tumour load in mice which implant Panc1_ctrl or Panc1_A8 cells. cyclo(RLsKDK) (TFA) improves the survival rate of pancreatic ductal adenocarcinoma (PDAC) mice, reduces solu Biological Activity:cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC 50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer.

C33H58F3N11O11

841.88 g/mol

H2O : 100 mg/mL (118.78 mM; Need ultrasonic)